Marex Group

Marex Group (also known as Marex, Inc.) was a marine biotechnology company primarily focused on the discovery and development of bioactive compounds derived from marine organisms. The company gained significant industry recognition for the discovery of Eleutherobin, a potent microtubule-stabilizing agent isolated from the soft coral Eleutherobia aurea. This compound, which shares a similar mechanism of action to paclitaxel, was subsequently licensed to Bristol-Myers Squibb for clinical development in oncology. Marex Group operated at the intersection of marine salvage and drug discovery, utilizing specialized exploration capabilities to access rare marine species for pharmacological screening. Although the company is no longer active, its contributions to marine-derived natural product chemistry remain a notable case study in pharmaceutical bioprospecting.